Efficacy of novel endoscopic hemostatic agent for bleeding control and prevention: Results from a prospective, multicenter national registry

Abstract

Background and study aims Topical hemostatic agents emerged as a new treatment modality for gastrointestinal bleeding. The aim of this study was to assess the safety and efficacy of PuraStat for control of active bleeding and for prevention of bleeding after different operative endoscopy procedures.

Patients and methods A national, multicenter, observational registry was established to collect data from ten Italian centers from June 2021 to February 2023. Demographics, type of application (active gastrointestinal bleeding or prevention after endoscopic procedures, site, amount of gel used, completeness of coverage of the treated area), outcomes (rates of intraprocedural hemostasis and bleeding events during 30-day follow-up), and adverse events (AEs) were prospectively analyzed.

Results Four hundred and one patients were treated for active gastrointestinal bleeding or as a preventive measure after different types of operative endoscopy procedures. Ninety-one treatments for active bleeding and 310 preventive applications were included. In 174 of 401 cases (43.4%), PuraStat was the primary treatment modality. Complete coverage was possible in 330 of 401 (82.3%) with difficulty in application in seven of 401 cases (1.7%). Hemostasis of active bleedings was achieved in 90 of 91 patients (98.9%). In 30-day follow-up 3.9% patients in whom PuraStat was used for prophylaxis had a bleeding event compared with 7.7% after hemostasis. No AEs related to the use of PuraStat were reported.

Conclusions PuraStat is a safe and effective hemostat both for bleeding control and for bleeding prevention after different operative endoscopy procedures. Our results suggest that the possible applications for the use of PuraStat may be wider compared with current indications.

Keywords

Endoscopy Upper GI Tract - Non-variceal bleeding - Endoscopy Lower GI Tract - Lower GI bleeding - Quality and logistical aspects - Performance and complications - Endoscopic resection (ESD, EMRc, ...) - Endoscopic resection (polypectomy, ESD, EMRc, ...)

Publikationsverlauf

Eingereicht: 09. April 2024

Angenommen nach Revision: 29. August 2024

Accepted Manuscript online:
18. September 2024

Artikel online veröffentlicht:
28. Oktober 2024

• References

• 1 Oakland K. Changing epidemiology and etiology of upper and lower gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2019; 42: 101610
• 2 Gralnek IM, Stanley AJ, Morris AJ. et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021. Endoscopy 2021; 53: 300-332
• 3 Triantafyllou K, Gkolfakis P, Gralnek IM. et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 850-868
• 4 Mourad FH, Leong RW. Role of hemostatic powders in the management of lower gastrointestinal bleeding: A review: Hemostatic agents lower intestinal bleed. J Gastroenterol Hepatol 2018; 33: 1445-1453
• 5 Vitali F, Naegel A, Atreya R. et al. Comparison of Hemospray and Endoclot for the treatment of gastrointestinal bleeding. World J Gastroenterol 2019; 25: 1592-1602
• 6 Wang T, Zhong X, Wang S. et al. Molecular mechanisms of RADA16–1 peptide on fast stop bleeding in rat models. Int J Mol Sci 2012; 13: 15279-15290
• 7 Jung JP, Gasiorowski JZ, Collier JH. Fibrillar peptide gels in biotechnology and biomedicine. Biopolymers 2010; 94: 49-59
• 8 Giritharan S, Salhiyyah K, Tsang GM. et al. Feasibility of a novel, synthetic, self-assembling peptide for suture-line haemostasis in cardiac surgery. J Cardiothorac Surg 2018; 13: 68
• 9 Masuhara H, Fujii T, Watanabe Y. et al. Novel infectious agent-free hemostatic material (TDM-621) in cardiovascular surgery. Ann Thorac Cardiovasc Surg 2012; 18: 444-451
• 10 Stenson KM, Loftus IM, Chetter I. et al. A multi-centre, single-arm clinical study to confirm safety and performance of PuraStat, for the management of bleeding in elective carotid artery surgery. Clin Appl Thromb Hemost 2022; 28 10760296221144307
• 11 Friedland Y, Bagot d’Arc M, Ha J. et al. The use of self-assembling peptides (PuraStat) in functional endoscopic sinus surgery for haemostasis and reducing adhesion formation. A case series of 94 patients. Surg Technol Int 2022; 42: sti41/1594
• 12 Lee MF, Ma Z, Ananda A. A novel haemostatic agent based on self-assembling peptides in the setting of nasal endoscopic surgery, a case series. Int J Surg Case Rep 2017; 41: 461-464
• 13 Wong E, Ho J, Smith M. et al. Use of Purastat, a novel haemostatic matrix based on self-assembling peptides in the prevention of nasopharyngeal adhesion formation. Int J Surg Case Rep 2020; 70: 227-229
• 14 Nahm CB, Popescu I, Botea F. et al. A multi-center post-market clinical study to confirm safety and performance of PuraStat in the management of bleeding during open liver resection. HPB (Oxford) 2022; 24: 700-707
• 15 Stefan S, Wagh M, Siddiqi N. et al. Self-assembling peptide haemostatic gel reduces incidence of pelvic collection after total mesorectal excision: Prospective cohort study. Ann Med Surg 2021; 68: 102553
• 16 Pioche M, Camus M, Rivory J. et al. A self-assembling matrix-forming gel can be easily and safely applied to prevent delayed bleeding after endoscopic resections. Endosc Int Open 2016; 4: E415-E419
• 17 Subramaniam S, Kandiah K, Thayalasekaran S. et al. Haemostasis and prevention of bleeding related to ER: The role of a novel self‐assembling peptide. United European Gastroenterol J 2019; 7: 155-162
• 18 Subramaniam S, Kandiah K, Chedgy F. et al. A novel self-assembling peptide for hemostasis during endoscopic submucosal dissection: a randomized controlled trial. Endoscopy 2021; 53: 27-35
• 19 Branchi F, Klingenberg-Noftz R, Friedrich K. et al. PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study. Surg Endosc 2022; 36: 2954-2961
• 20 de Nucci G, Reati R, Arena I. et al. Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding. Endoscopy 2020; 52: 773-779
• 21 Kubo K, Hayasaka S, Tanaka I. Endoscopic hemostatic treatment for acute gastrointestinal bleeding by combined modality therapy with PuraStat and endoscopic hemoclips. Case Rep Gastroenterol 2023; 17: 89-95
• 22 Gagliardi M, Oliviero G, Fusco M. et al. Novel hemostatic gel as rescue therapy for postsphincterotomy bleeding refractory to self-expanding metallic stent placement. ACG Case Rep J 2022; 9: e00744
• 23 Ishida Y, Tsuchiya N, Koga T. et al. A novel self-assembling peptide hemostatic gel as an option for initial hemostasis in endoscopic sphincterotomy-related hemorrhage: a case series. Clin J Gastroenterol 2022; 15: 1210-1215
• 24 Uba Y, Ogura T, Ueno S. et al. Comparison of endoscopic hemostasis for endoscopic sphincterotomy bleeding between a novel self-assembling peptide and conventional technique. J Clin Med 2022; 12: 79
• 25 Ogura T, Uba Y, Yamamura M. et al. Endoscopic hemostasis using self-expandable metal stent combined with PuraStat for patient with high risk of post-endoscopic sphincterotomy bleeding (with video). Hepatobiliary Pancreat Dis Int 2024; 23: 94-96
• 26 Yamamoto K, Sofuni A, Mukai S. et al. Use of a novel self‐assembling hemostatic gel as a complementary therapeutic tool for endoscopic sphincterotomy‐related bleeding. J Hepatobiliary Pancreat Sci 2022; 29: e81-e83
• 27 Miyano A, Ogura T, Nishikawa H. Noninvasive endoscopic hemostasis technique for post‐papillectomy bleeding using a novel self‐assembling peptide (with video). JGH Open 2023; 7: 81-82
• 28 Yamamoto K, Tsuchiya T, Tonozuka R. et al. Novel self‐assembling hemostatic agent with a supportive role in hemostatic procedures for delayed bleeding after endoscopic papillectomy. J Hepatobiliary Pancreat Sci 2023; 30: e22-e24
• 29 Misumi Y, Takeuchi M, Kishino M. et al. A case of gastric antral vascular ectasia in which PuraStat, a novel self‐assembling peptide hemostatic hydrogel, was effective. DEN Open 2023; 10: e183
• 30 White K, Henson CC. Endoscopically delivered Purastat for the treatment of severe haemorrhagic radiation proctopathy: a service evaluation of a new endoscopic treatment for a challenging condition. Frontline Gastroenterol 2021; 12: 608-613
• 31 Binda C, Fugazza A, Fabbri S. et al. The use of PuraStat in the Management of walled-off pancreatic necrosis drained using lumen-apposing metal stents: a case series. Medicina (Kaunas) 2023; 59: 750
• 32 Gagliardi M, Sica M, Oliviero G. et al. Endoscopic application of Purastat in the treatment of solitary rectal ulcer syndrome. J Gastrointestin Liver Dis 2021;
• 33 Soriani P, Biancheri P, Deiana S. et al. Off-label PuraStat use for the treatment of acute intrahepatic biliary duct bleeding. Endosc Int Open 2021; 9: E1926-E1927
• 34 Nakahara K, Michikawa Y, Sato J. et al. A novel self‐assembling peptide hemostatic gel as rescue therapy for fistula bleeding after endoscopic ultrasound‐guided hepaticogastrostomy. J Hepatobiliary Pancreat Sci 2023; 30: e66-e67
• 35 Kubo K. Delayed bleeding following percutaneous endoscopic gastrostomy successfully treated with PuraStat. Intern Med 2023; 62: 487-488